Search Results

The product title you are looking for is no longer available. Other similar products that may interest you are listed below:

Refine your Search

Results for 'Ovarian Cancer Drug Pipeline Report'
Title Publication Date Price Relevance
Ovarian Cancer Drug Pipeline Update 2009 Jan 2009 £1,245 100%
Ovarian Cancer Drug Pipeline Update 2011 Feb 2011 £1,245 99%
Ovarian Cancer - Pipeline Review
H1 2012
 Jan 2012 £325 99%
Stakeholder Opinions: Ovarian Cancer
Approaching the era of molecular targeted therapy
 Jul 2010 £2,405 98%
Ovarian Cancer Therapy Area Pipeline Report Mar 2011 £945 97%
Ovarian Cancer Therapeutics
Pipeline Assessment and Market Forecasts to 2017
 Dec 2010 £1,265 97%
Oncology Therapeutics Market to 2017
High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development
 Dec 2011 £2,215 95%
Endpoints-Clinical Trials in Orphan Diseases
Highest Number of Terminated Trials Focused on Mulitiple Myeloma
 Jan 2012 £2,215 95%
Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020 Jan 2012 £1,265 94%
Clinical Trial Endpoints in Oncology
Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology
 Mar 2011 £2,215 93%
Paclitaxel (Ovarian Cancer)
Analysis and Forecasts to 2020
 Sep 2011 £1,265 93%
Opaxio (Ovarian Cancer) – Analysis and Forecasts to 2020 Oct 2011 £1,265 92%
Yondelis (Ovarian Cancer) - Analysis and Forecasts to 2020 Sep 2011 £1,265 92%
Paclical (Ovarian Cancer) – Analysis and Forecasts to 2020 Oct 2011 £1,265 92%
Farletuzumab (Ovarian Cancer) – Analysis and Forecasts to 2020 Oct 2011 £1,265 92%
Cisplatin (Ovarian Cancer) – Analysis and Forecasts to 2020 Oct 2011 £1,265 92%
Recentin (Ovarian Cancer) – Analysis and Forecasts to 2020 Oct 2011 £1,265 92%
Karenitecin (Ovarian Cancer) – Analysis and Forecast to 2020 Oct 2011 £1,265 92%
EC145 (Ovarian Cancer) – Analysis and Forecasts to 2020 Oct 2011 £1,265 92%
Olaparib (Ovarian Cancer) – Analysis and Forecasts to 2020 Oct 2011 £1,265 92%
Carboplatin (Ovarian Cancer) – Analysis and Forecasts to 2020 Oct 2011 £1,265 92%
Votrient (Ovarian Cancer) – Analysis and Forecasts to 2020 Oct 2011 £1,265 92%
Gemzar (Ovarian Cancer) – Analysis and Forecasts to 2020 Oct 2011 £1,265 92%
Vargatef (Ovarian Cancer) – Analysis and Forecats to 2020 Oct 2011 £1,265 92%
Avastin (Ovarian Cancer) – Analysis and Forecasts to 2020 Oct 2011 £1,265 92%
Hycamtin (Ovarian Cancer) – Analysis and Forecasts to 2020 Oct 2011 £1,265 92%
AMG 386 (Ovarian Cancer) – Analysis and Forecasts to 2020 Oct 2011 £1,265 92%
Nektar Therapeutics – Product Pipeline Review
H2 2011
 Nov 2011 £315 90%
Telik, Inc. – Product Pipeline Review
H2 2011
 Nov 2011 £315 90%
BioCancell Therapeutics, Inc. – Product Pipeline Review
H2 2011
 Dec 2011 £315 90%